Differentiating rare salivary gland-type tumors from benign or borderline proliferations remains a formidable challenge in breast oncology. Specifically, breast adenoid cystic carcinoma represents an uncommon malignancy that exhibits a dual epithelial and myoepithelial differentiation pattern. Although this tumor belongs biologically to triple-negative breast cancers, it usually follows an indolent clinical trajectory. Nevertheless, diagnostic confusion frequently arises during percutaneous tissue sampling because its architectural motifs overlap considerably with benign entities. Therefore, clinicians must carefully correlate core needle biopsy findings with radiological imaging to avoid critical undertreatment or delayed intervention.

Clinical Presentation and Diagnostic Pitfalls of Breast Adenoid Cystic Carcinoma

Breast adenoid cystic carcinoma accounts for less than one percent of all primary mammary neoplasms. In clinical practice, patients typically present in their fifth or sixth decade of life with a solitary, palpable mass. However, multifocal presentations can occasionally occur and create substantial diagnostic ambiguity. For example, clinicians recently reported a case involving a fifty-two-year-old woman presenting with two separate right breast masses along the same radial axis. One lesion occupied an anterior position, while the other lesion was located deeper in the posterior parenchyma. Percutaneous core needle biopsies initially suggested two entirely distinct pathologies. The anterior lesion showed atypical ductal hyperplasia, whereas the posterior lesion exhibited features of adenomyoepithelioma. Consequently, these disparate biopsy results masked the underlying malignant reality until definitive surgical resection took place. Histopathological examination of the excised specimens subsequently demonstrated invasive adenoid cystic carcinoma in both locations. This significant discrepancy emphasizes how limited percutaneous biopsy samples may capture only non-representative peripheral components of a complex tumor. Therefore, clinicians must maintain high clinical suspicion when multiple lesions demonstrate atypical or discordant characteristics on pre-operative core biopsies.

Histological Overlap Between Adenomyoepithelioma and Malignancy

The diagnostic dilemma between adenomyoepithelioma and adenoid cystic carcinoma stems directly from their shared biphasic nature. Both neoplasms feature a prominent dual proliferation of inner luminal epithelial cells and outer myoepithelial cells. In adenomyoepithelioma, benign myoepithelial cells surround regular tubular spaces without infiltrative invasion. In contrast, adenoid cystic carcinoma displays classic tubular, cribriform, and solid-basaloid growth patterns accompanied by extracellular basement membrane deposits. Furthermore, true cribriform spaces contain rounded pseudo-lumens filled with basement membrane material alongside true glandular lumens lined by epithelial cells. When pathologists examine limited core needle biopsy cores, they may fail to capture these defining cribriform arrangements. Instead, they might observe only solid nests or proliferating spindle and clear cells that mimic benign adenomyoepithelial proliferations. Moreover, reactive stromal changes and associated atypical ductal hyperplasia around the tumor periphery can easily mislead the examining pathologist. Immunohistochemistry assists substantially in resolving this diagnostic puzzle. Specifically, adenoid cystic carcinoma demonstrates strong c-kit positivity within luminal epithelial cells, whereas adenomyoepithelioma consistently lacks this distinctive marker. In addition, the characteristic MYB-NFIB gene fusion serves as a definitive molecular hallmark for adenoid cystic carcinoma. Consequently, comprehensive histological and immunohistochemical evaluation of entire resected tissue remains essential whenever core biopsies yield borderline or conflicting biphasic proliferations.

Radiological Evaluation and Image-Guided Biopsy Discrepancies

Accurate radiologic evaluation plays a pivotal role in detecting suspicious breast lesions and planning definitive interventions. On mammography, breast adenoid cystic carcinoma typically presents as an irregular or microlobulated mass with indistinct or spiculated margins. Calcifications appear infrequently, although some patients exhibit subtle fine pleomorphic calcifications within dense tissue. Ultrasound examination usually reveals a hypoechoic or heterogeneous solid mass, often displaying notable internal vascularity on color Doppler imaging. Furthermore, posterior acoustic enhancement or mild shadowing may accompany the solid component. In cases where multiple lesions exist, choosing the appropriate biopsy modality is critical. For instance, radiologists often employ ultrasound-guided core needle biopsy for accessible anterior lesions while reserving stereotactic core biopsy for deeper calcified or posterior masses. However, image-guided biopsy techniques still carry an inherent risk of sampling error. A small needle core might sample adjacent fibrocystic change or secondary hyperplasia rather than the central malignant nidus. Therefore, breast radiologists and surgeons must systematically evaluate radiologic-pathologic concordance before finalizing a patient management plan. If imaging demonstrates features suggestive of malignancy but needle histology reports only a benign or low-risk diagnosis, physicians must consider the biopsy discordant. Consequently, discordant findings mandate immediate surgical re-evaluation or prompt excisional biopsy.

Surgical Management and Long-Term Oncological Outcomes

Surgical resection serves as the primary curative modality for localized adenoid cystic carcinoma of the breast. Surgeons can achieve excellent locoregional control through breast-conserving lumpectomy or total mastectomy, depending on tumor extent and breast size. In multifocal disease, total mastectomy often represents the safest strategy to achieve negative surgical margins. Unlike aggressive triple-negative ductal carcinomas, adenoid cystic carcinoma rarely metastasizes to axillary lymph nodes. In fact, regional nodal involvement occurs in less than two to five percent of reported cases. Because of this low nodal propensity, routine axillary lymph node dissection is rarely necessary, though surgeons frequently perform sentinel lymph node biopsy for accurate staging. Furthermore, mammary adenoid cystic carcinoma demonstrates an exceptionally favorable long-term prognosis. Ten-year overall survival rates consistently exceed ninety percent in clinical cohorts. Notably, the fifty-two-year-old patient described in the literature remained completely disease-free ten years after undergoing total mastectomy without any adjuvant chemotherapy or radiation. Because these tumors typically exhibit low proliferation indices and hormone receptor negativity, standard adjuvant chemotherapy regimens offer minimal therapeutic benefit. Nevertheless, clinicians must maintain extended post-operative surveillance because late recurrences can occasionally arise decades after initial surgery.

Clinical Implications and Best Practices for Breast Specialists

The deceptive histological mimicry between breast adenoid cystic carcinoma and benign proliferations provides vital lessons for multidisciplinary breast care teams. First, clinicians should never dismiss discordant core needle biopsy results when pre-operative imaging raises clinical concern. A diagnosis of adenomyoepithelioma or atypical ductal hyperplasia on a percutaneous core biopsy should prompt immediate discussion at a multidisciplinary tumor board. Second, high-risk biphasic lesions warrant complete surgical excision with clear margins to exclude underlying invasive malignancy. Complete tissue removal allows comprehensive histopathological analysis, eliminating the diagnostic limitations imposed by restricted percutaneous tissue fragments. Third, pathologists should routinely utilize an immunohistochemical panel comprising p63, calponin, and c-kit to differentiate complex biphasic neoplasms accurately. In equivocal cases, molecular testing for the recurrent MYB-NFIB translocation can provide definitive diagnostic confirmation. Finally, clinicians must recognize that favorable biological behavior does not preclude the need for rigorous, long-term clinical surveillance. Late distant metastases, particularly to the pulmonary parenchyma, can emerge silently years later. Therefore, establishing a systematic follow-up protocol ensures prompt detection and intervention. Through meticulous multidisciplinary collaboration, surgical oncologists and pathologists can avoid diagnostic pitfalls and deliver optimal, individualized patient care.

Frequently Asked Questions

Why does core needle biopsy sometimes misdiagnose breast adenoid cystic carcinoma?

Core needle biopsy extracts only a tiny tissue cylinder, which may capture non-representative peripheral zones rather than the diagnostic malignant core. Because breast adenoid cystic carcinoma possesses a biphasic population of epithelial and myoepithelial cells, limited fragments can closely resemble benign adenomyoepithelioma or atypical ductal hyperplasia. Pathologists often miss characteristic cribriform spaces or basement membrane cylinders on small cores, highlighting the crucial need for complete surgical excision and thorough multidisciplinary radiologic-pathologic correlation.

How does the prognosis of breast adenoid cystic carcinoma differ from standard triple-negative breast cancer?

Although breast adenoid cystic carcinoma usually tests negative for estrogen, progesterone, and HER2 receptors, its clinical behavior differs dramatically from standard aggressive triple-negative ductal carcinomas. Standard triple-negative breast cancer features high proliferation indices and high recurrence rates. In sharp contrast, adenoid cystic carcinoma follows an indolent course, exhibits low proliferation markers, and rarely metastasizes to axillary lymph nodes. Ten-year relative survival rates consistently surpass ninety percent, allowing many patients to achieve long-term remission without adjuvant systemic chemotherapy.

What is the recommended management when a core needle biopsy reveals adenomyoepithelioma?

When a percutaneous core needle biopsy indicates adenomyoepithelioma, clinicians should recommend complete surgical excision with clean margins. Even though adenomyoepithelioma is primarily a benign neoplasm, it carries a distinct risk of local recurrence and can harbor malignant components. Furthermore, complete surgical excision rules out invasive malignancies like adenoid cystic carcinoma that closely imitate adenomyoepithelioma on limited core samples. Multidisciplinary review and definitive histopathological evaluation of the entire excised specimen ensure accurate diagnosis and appropriate long-term monitoring.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Chandlee ET et al. Imaging of Multifocal Adenoid Cystic Carcinoma of the Breast Initially Diagnosed as Adenomyoepithelioma on Core Needle Biopsy: A Case Report. Cureus. 2026 Sep undefined. doi: 10.7759/cureus.116150. PMID: 42732445.
2. Di Bonito M, Cantile M, Collina F, et al. Breast Adenoid Cystic Carcinoma: Recognizing a Rare Pathological Diagnosis. Diagnostics. 2026;16(2):186.
3. Kim M, Park VY, Yoon JH, et al. Adenoid Cystic Carcinoma of the Breast: Clinical and Radiological Findings. Diagnostics (Basel). 2026;16(12):1869.